ReviewObstetrics and gynecology2018
Maternal Malignancy Evaluation After Discordant Cell-Free DNA Results.
Review in Obstetrics and gynecology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Society for Maternal-Fetal Medicine Consult Series #74: Cell-free DNA screening for aneuploidies: Updated guidance.Pregnancy (Hoboken, N.J.) · 2025Article
- Prenatal cfDNA Sequencing and Incidental Detection of Maternal Cancer.The New England journal of medicine · 2024Observational
- Non-invasive prenatal testing: when results suggests maternal cancer.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2023Article
- The radiologist's role in a multidisciplinary approach to cancer in pregnancy.Abdominal radiology (New York) · 2023Review
- Noninvasive prenatal screening and maternal malignancy: role of imaging.Abdominal radiology (New York) · 2023Review
- Incidental finding of maternal malignancy in an unusual non-invasive prenatal test and a review of similar cases.Clinical case reports · 2022Article
- More than an Incidentaloma: The Nonreportable NIPT.Case reports in obstetrics and gynecology · 2022Article
- Comprehensive genome-wide analysis of routine non-invasive test data allows cancer prediction: A single-center retrospective analysis of over 85,000 pregnancies.EClinicalMedicine · 2021Article
- First Case Report of Maternal Mosaic Tetrasomy 9p Incidentally Detected on Non-Invasive Prenatal Testing.Genes · 2021Article
- Diagnosis of maternal Hodgkin lymphoma following abnormal findings at noninvasive prenatal screening test (NIPT): Report of two cases.Clinical case reports · 2021Article
- Noninvasive prenatal testing: from aneuploidy to single genes.Human genetics · 2020Review
- Genome-wide noninvasive prenatal diagnosis of monogenic disorders: Current and future trends.Computational and structural biotechnology journal · 2020Review
- Identifying occult maternal malignancies from 1.93 million pregnant women undergoing noninvasive prenatal screening tests.Genetics in medicine : official journal of the American College of Medical Genetics · 2019Article
- Current Controversies in Prenatal Diagnosis 2: NIPT results suggesting maternal cancer should always be disclosed.Prenatal diagnosis · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cell-free DNA screening for fetal aneuploidy is a commonly used testing strategy in pregnancies at high risk for fetal aneuploidy. The use of cell-free DNA screening is expanding to the low-risk population, because the detection rate for trisomy 21 surpasses that of traditional screening modalities. Although the sensitivity and specificity of cell-free DNA are superior to traditional screening, false-positive results do occur and may indicate an adverse maternal health condition, including maternal mosaicism or, rarely, malignancy. The risk of maternal cancer is significantly elevated when more than one aneuploidy is detected that is discordant from fetal karyotype. Given this risk as well as the rising incidence of cancer in pregnancy, patient counseling and malignancy evaluation should be considered in women when more than one aneuploidy is detected. We reviewed the published literature and developed an algorithm to evaluate women when these results are identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.